A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

The former vice president of a Carmel Valley pharmaceutical company pleaded guilty Friday to a federal securities fraud count ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

The former vice president of a San Diego-based pharmaceutical company pleaded guilty Friday to a federal securities fraud ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...